Coherus Tagmokitug Hits 75% ORR in Front-Line Esophageal Cancer
CHRS is trading near its 52-week low of $0.94 (12% above the low).
Summary
Interim tagmokitug data from Coherus showed a 75% confirmed response rate in previously untreated esophageal cancer (89% after later confirmations) and durable benefit in second-line disease — the first clinical proof of concept for its CCR8 antibody.
Key Events · Product Development and Regulatory · CHRS
-
Front-Line ESCC Response Rate of 75%
Among 8 efficacy-evaluable previously untreated ESCC patients, tagmokitug 700 mg plus toripalimab and chemotherapy produced a confirmed ORR of 75% (6/8) irrespective of PD-L1 status and 100% in PD-L1 positive patients as of the October 14, 2026 cutoff.
-
Post-Cutoff ORR Rises to 89%
Two additional partial responses confirmed after the cutoff lifted the confirmed ORR to 89% (8/9) of the evaluable dataset, including one confirmed complete response.
-
Second-Line Dose Response at 700 mg
In the 700 mg arm, cORR was 16.7% (1/6), clinical benefit rate 33.3% (2/6) and median PFS 5.5 months, versus a roughly 3.4-month chemotherapy benchmark; the 300 mg arm had only 2 evaluable patients.
-
Activity Across Five Indications
Upper GI tumors showed 23.5% cORR (4/17) at 700 mg including PD-1 resistance rescue, HPV-positive head and neck 13.0% cORR (3/23), and heavily pretreated colorectal cancer 5.9% cORR (1/17).
Analysis · CHRS · Life Sciences
The first hard efficacy data on tagmokitug, Coherus's CCR8 antibody, now give the program clinical proof of concept in esophageal squamous cell carcinoma. Front-line confirmed ORR reached 75% (6/8) regardless of PD-L1 status and 100% in PD-L1 positive patients, rising to 89% (8/9) after two additional responses were confirmed; for context, PD-1 plus chemotherapy benchmarks at a 44%-59% confirmed ORR in PD-L1 positive disease. Second-line patients also showed a dose response at 700 mg, with a 5.5-month median PFS versus roughly 3.4 months for chemotherapy. The datasets remain small (8-9 efficacy-evaluable patients in front line, 6 in the 700 mg second-line arm) and enrollment is ongoing, so the numbers will move as they mature. Still, this is the asset carrying the pipeline story while the company markets its legacy biosimilar assets, and a credible ESCC signal materially raises the odds of a partnership or a larger development path.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRS was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $179.2M. The 52-week trading range was $0.94 to $2.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.